本帖最后由 老马 于 2012-1-13 21:20 编辑
) z# ^- J& Y' F+ R* k
' u( D( a$ c y' w爱必妥和阿瓦斯丁的比较3 K. `) V4 M. M
: g1 ?% M" @4 u( N. Lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
$ a4 e: S' U, \( c3 P [
: U/ e0 P' w0 b& _
/ f8 f4 W/ _6 E
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 l3 C& w- H5 |+ F& p8 r- H2 i2 T6 \- V
==================================================
7 P" P2 q& I1 o2 g8 h8 `Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)- v" O3 l6 q' ~* H
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.$ Q% G! O# U* }5 Y- Z7 u. H- [
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 i3 V9 ?2 y; @$ l0 Y
|